Blade Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–#Autotaxin–Blade Therapeutics today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the 39^th Annual J.P. Morgan Healthcare Conference. The virtual session will take place on Thursday, January 14, 2021, at 11:35 a.m. – 12:00 p.m. Eastern Time. A link to the live and archived webcast presentation can be accessed on the “News & Events” page of the Blade company website at https://www.blademed.com/news/events/.

About Blade Therapeutics

Blade Therapeutics is a private biopharmaceutical company founded on a commitment to revolutionize the treatment of debilitating, incurable fibrotic diseases that impact millions of people worldwide. The Company is an expert in novel biological pathways – including autotaxin / LPA and calpain biology – that are foundational to cell and tissue damage responses leading to fibrosis. Blade is advancing a robust pipeline of potential first- and best-in-class investigational therapies for diseases of lung, liver and heart fibrosis, as well as neuro-degenerative diseases. This includes multiple small-molecule direct inhibitors of autotaxin / LPA and dimeric calpains that offer distinct but complementary anti-fibrotic mechanisms. (Read more…)

Since its founding in 2015, Blade has raised approximately $90 million, including investments from Deerfield Management, MPM Capital, Pfizer Ventures, One Ventures, Osage University Partners and pharma strategic investments from Bristol-Myers Squibb and Novartis Institutes for Biomedical Research. The Company has assembled critical leadership expertise supplemented by a world-class network of scientific, pharmaceutical and clinical advisors to enable efficient and successful drug development. Visit www.blademed.com for more information.

About Fibrosis

Fibrosis is a complex, pathologic process involving the development of fibrous connective tissue (scarring) within various organs. This process may be triggered by a dysregulated response to cellular injury, inflammation, genetic signaling, metabolism or toxins. Once present, normal cellular function is impeded. Later-stage fibrotic disease is marked by poor outcomes and high morbidity and mortality. Diseases characterized by uncontrolled, progressive fibrosis include idiopathic pulmonary fibrosis (IPF), interstitial lung disease (ILD) and non-alcoholic steatohepatitis (NASH). New safe, well-tolerated therapies that provide robust attenuation of disease progression are urgently needed to address the high burden of fibrotic diseases.

Contacts

Media Relations – Michael Blash

[email protected]
+1-650-453-0632

Investor Relations – Krishna Gorti, M.D.

[email protected]
+1-650-797-0314